Disease Domain | Count |
---|---|
Infectious Diseases | 8 |
Neoplasms | 7 |
Hemic and Lymphatic Diseases | 2 |
Immune System Diseases | 1 |
Top 5 Drug Type | Count |
---|---|
Monoclonal antibody | 17 |
Unknown | 1 |
Fusion protein | 1 |
Target |
Mechanism OX40L inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhasePhase 3 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism ICOS agonists |
Active Org. |
Originator Org. |
Active Indication- |
Inactive Indication- |
Drug Highest PhasePhase 1/2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism- |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date13 Dec 2021 |
Sponsor / Collaborator ![]() [+1] |
Start Date07 Jul 2020 |
Sponsor / Collaborator |
Start Date28 Jan 2019 |
Sponsor / Collaborator ![]() [+1] |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Alomfilimab ( ICOS ) | Squamous Cell Carcinoma of Head and Neck More | Phase 2 Clinical |
Amlitelimab ( OX40L ) | Eczema More | Phase 2 |
KY-1070 ( BMP6 ) | Anemia More | Preclinical |
KY-7001 | Infectious Diseases More | Preclinical |
KY-7003 | Infectious Diseases More | Preclinical |